tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aurinia Pharmaceuticals Reaffirms Confidence in LUPKYNIS After Retraction
PremiumCompany AnnouncementsAurinia Pharmaceuticals Reaffirms Confidence in LUPKYNIS After Retraction
1M ago
Aurinia drops after FDA official criticizes voclosporin
Premium
The Fly
Aurinia drops after FDA official criticizes voclosporin
1M ago
Promising Drug Pipeline and Positive Trial Results Drive Buy Rating for Aurinia Pharmaceuticals
Premium
Ratings
Promising Drug Pipeline and Positive Trial Results Drive Buy Rating for Aurinia Pharmaceuticals
2M ago
Optimistic Buy Rating for Lupkynis Driven by Strong Sales and Promising Clinical Developments
PremiumRatingsOptimistic Buy Rating for Lupkynis Driven by Strong Sales and Promising Clinical Developments
3M ago
Aurinia Pharmaceuticals Reports Strong Revenue Growth and Expands Share Repurchase Plan
Premium
Company Announcements
Aurinia Pharmaceuticals Reports Strong Revenue Growth and Expands Share Repurchase Plan
3M ago
Aurinia Pharmaceuticals raises 2025 revenue view to $260M-$270M from $250M-$260M
Premium
The Fly
Aurinia Pharmaceuticals raises 2025 revenue view to $260M-$270M from $250M-$260M
3M ago
Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept
PremiumCompany AnnouncementsAurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept
4M ago
Aurinia Pharma reports ‘positive’ results from Phase 1 study of aritinercept
Premium
The Fly
Aurinia Pharma reports ‘positive’ results from Phase 1 study of aritinercept
4M ago
Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results
Premium
Company Announcements
Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100